Ramsay Health Care

The Business

Ramsay operates 70 hospitals across Australia, commanding roughly a quarter of the private hospital market in an industry effectively controlled by two players. The Australian division generates around 72% of the post-demerger group's revenue, supplemented by UK acute hospitals and Elysium, a struggling UK mental health operation. Most revenue is contracted with private health insurers or government payors, making demand clinically driven rather than discretionary. Ramsay is separating its loss-making European arm, Ramsay Santé, by December 2026, leaving a simpler, higher-returning Australian and UK business behind.

Recent Performance

Group revenue reached $9,423 million in FY26, up 5.5% on a base that itself grew solidly, while EBITDA margin expanded 50 basis points to 13.2%. Earnings momentum has been genuine: admissions grew 3.3% and theatre utilisation climbed toward 70% of capacity, driving operating leverage. The share price has moved well ahead of this operational improvement, and the current price requires several favourable assumptions to hold at once, particularly around interest rates and the durability of recent margin gains.

Outlook

Revenue growth is expected to moderate over the next few years as post-pandemic catch-up in admissions fades and private health insurance indexation settles into a steadier pattern. EBITDA margin should continue expanding in the near term, supported by rising theatre utilisation, procurement savings and revenue cycle improvements already partly visible in the FY26 result, before the pace of improvement slows as these efficiency gains mature. Beyond the current forecast window, margins are expected to drift back toward long-run averages as competitive and payor dynamics reassert themselves, a pattern typical of a mature, regulated healthcare market rather than one structurally re-rating higher.

Our Valuation

We built our fair value estimate from three independent approaches: discounted cash flow, trading multiples and transaction multiples. The methods converge within a reasonably tight range, which gives us confidence the estimate is not being driven by any single aggressive assumption. Weighing the current price against that work is where the analysis becomes decision-relevant, and it is the piece we reserve for subscribers.

Key Risks

Health insurer pushback on indexation is the largest identified risk, since Australia represents roughly 72% of post-demerger revenue and any compression in Australian margins flows straight to the bottom line. Persistently high interest rates present a second, related risk: elevated financing costs and discount rates both work against the stock, and this is also the mirror image of the largest upside catalyst, since falling rates would work in the opposite direction. Elysium's structural decline is the third risk, as UK mental health commissioning shifts away from hospital beds toward community-based care, a trend that is unlikely to reverse regardless of near-term cost cutting.

What to Watch

The thesis-defining event is the Ramsay Santé demerger process running through late 2026, which will confirm what the European business is actually worth once it trades as a standalone entity, rather than what either side currently assumes.

• Nov 2026 Santé demerger shareholder vote — expected to pass, removing a loss-making, highly leveraged distraction from group accounts.
• Feb 2027 RBA rate decision — easing monetary policy would reduce the discount rate applied to future cash flows, a key support for the more optimistic end of the outcome range.

Company Description

Ramsay's Australian division, roughly 72% of post-demerger revenue, operates 70 private hospitals spanning acute surgical, rehabilitation and psychiatric care, funded predominantly through private health insurance. The UK Acute division runs private hospitals serving both NHS-referred and self-funded patients. Elysium, a UK mental health and specialist care operator, is the smallest and weakest segment, facing structural declines as NHS commissioning shifts patients toward community-based care rather than hospital beds. Ramsay Santé, the European arm covering France and the Nordics, is being demerged from the group entirely by December 2026, distributed to shareholders as a separately listed entity.

Where the Growth Is

The Australian division is doing the heavy lifting. Theatre utilisation is climbing from 70% toward a targeted 73% of capacity, while private health insurance coverage grows roughly 2.5% annually on the back of an aging population. Combined with procurement savings and administrative efficiency gains, this underpins the case for further EBITDA margin expansion from the current 13.2%, though the pace of improvement is expected to slow once these efficiency programs are fully realised.

Competitive Position

Ramsay's advantage rests on catchment-level scale: doctors build referral relationships over decades with specific hospitals, and once established, those relationships are costly for a competitor to dislodge. With roughly a quarter of the Australian private hospital market and only one comparably sized rival, pricing tends to be rational rather than aggressively competitive. This advantage is durable but not indefinite. We see it holding for around seven years before competitive or regulatory pressures are likely to erode the current economics, and Ramsay's market share has been stable rather than expanding, suggesting the moat protects existing earnings more than it drives new growth.

Management & Capital Discipline

Management has run a conservative capital allocation program: leverage has been reduced, the dividend reinvestment plan is suspended, and buybacks are absent, with the one recent acquisition (National Capital, $251 million) modest relative to group size. Management has been transparent about weak demand at Elysium rather than dressing it up, which supports credibility. Less discussed is that some of the recent margin improvement reflects industry-wide private health insurance indexation gains rather than company-specific execution, a distinction management does not always draw clearly in its commentary.

Financial Position

The post-demerger Funding Group carries manageable leverage with net debt around 1.5 times EBITDA, expected to decline further as free cash flow builds. Roughly 60% of debt is hedged at an average rate of 3.6%, limiting near-term exposure to further rate rises. The balance sheet can comfortably absorb a moderate earnings downturn, though heavy lease obligations mean returns on capital remain sensitive to the prevailing cost of debt.